Globe Newswire09.20.18
BioSig Technologies Inc. has partnered with Amy Ansfield Scott to assist with nationwide KOL engagement ahead of the commercial launch of PURE EP System in the United States.
Scott brings to the company over 30 years of experience in medical devices, including over 20 years in electrophysiology (EP). Most recently, she served as director of Strategic Partnerships for Biosense Webster (Johnson & Johnson), a role which she was responsible for primarily U.S. engagement of physicians and management of the company’s Scientific Advisory Board. Prior to that role, Scott was managing a team responsible for driving customer engagement and education, including development of product demonstration and training sites, management of key accounts and liaison between internal clinical and field clinical trials teams. During her career with Biosense Webster, Scott also served as global product director for Atrial Fibrillation, the role in which she developed, executed and managed EP/Afib Centers of Excellence. She brings to BioSig extensive experience in defining customer needs and promoting key account relations and activities.
“An experienced and passionate leader like Amy is an invaluable addition to our team. Her expertise in building successful physician relationships and the depth of her marketing knowledge can significantly benefit our effort to launch and expand our clinical operations following our 510(k) clearance,” stated Kenneth Londoner, chairman and CEO of BioSig Technologies Inc.
The company received U.S. Food and Drug Administration 510(k) clearance for its PURE EP System on Aug. 14. Earlier last month, BioSig Technologies announced its intentions to list on the Nasdaq stock exchange.
“I’m delighted to join the BioSig team as the Company starts a new chapter. I have been impressed with the strong value proposition of PURE EP and the long-term vision of the management team. I look forward to helping the company make its first steps in the clinical field,” commented Scott.
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles, Calif.-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation, and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development.
Scott brings to the company over 30 years of experience in medical devices, including over 20 years in electrophysiology (EP). Most recently, she served as director of Strategic Partnerships for Biosense Webster (Johnson & Johnson), a role which she was responsible for primarily U.S. engagement of physicians and management of the company’s Scientific Advisory Board. Prior to that role, Scott was managing a team responsible for driving customer engagement and education, including development of product demonstration and training sites, management of key accounts and liaison between internal clinical and field clinical trials teams. During her career with Biosense Webster, Scott also served as global product director for Atrial Fibrillation, the role in which she developed, executed and managed EP/Afib Centers of Excellence. She brings to BioSig extensive experience in defining customer needs and promoting key account relations and activities.
“An experienced and passionate leader like Amy is an invaluable addition to our team. Her expertise in building successful physician relationships and the depth of her marketing knowledge can significantly benefit our effort to launch and expand our clinical operations following our 510(k) clearance,” stated Kenneth Londoner, chairman and CEO of BioSig Technologies Inc.
The company received U.S. Food and Drug Administration 510(k) clearance for its PURE EP System on Aug. 14. Earlier last month, BioSig Technologies announced its intentions to list on the Nasdaq stock exchange.
“I’m delighted to join the BioSig team as the Company starts a new chapter. I have been impressed with the strong value proposition of PURE EP and the long-term vision of the management team. I look forward to helping the company make its first steps in the clinical field,” commented Scott.
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles, Calif.-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation, and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development.
